对雷博替尼耐药的L2086F突变ROS1重排NSCLC对卡博替尼有反应：一份病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-07-01 DOI:10.1016/j.jtocrr.2024.100673

{"title":"对雷博替尼耐药的L2086F突变ROS1重排NSCLC对卡博替尼有反应：一份病例报告","authors":"","doi":"10.1016/j.jtocrr.2024.100673","DOIUrl":null,"url":null,"abstract":"<div>Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against G2032R, the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretreated, with advanced L1951R and L2026M mutated ROS1-rearranged NSCLC, who initially responded to repotrectinib but later developed further on-target resistance with the emergence of an L2086F mutation. The disease then responded to cabozantinib, a separate class of ROS1 TKI with preclinical activity against L2086F.</div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 7","pages":"Article 100673"},"PeriodicalIF":3.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000432/pdfft?md5=f04737e16c25c15801d9a2787e2aa0ce&pid=1-s2.0-S2666364324000432-main.pdf","citationCount":"0","resultStr":"{\"title\":\"L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report\",\"authors\":\"\",\"doi\":\"10.1016/j.jtocrr.2024.100673\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against G2032R, the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretreated, with advanced L1951R and L2026M mutated ROS1-rearranged NSCLC, who initially responded to repotrectinib but later developed further on-target resistance with the emergence of an L2086F mutation. The disease then responded to cabozantinib, a separate class of ROS1 TKI with preclinical activity against L2086F.</div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 7\",\"pages\":\"Article 100673\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000432/pdfft?md5=f04737e16c25c15801d9a2787e2aa0ce&pid=1-s2.0-S2666364324000432-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000432\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000432","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Repotrectinib于2023年11月获得许可，是一种新型ROS1酪氨酸激酶抑制剂（TKI），对G2032R具有活性，G2032R是前几代ROS1 TKIs最常见的耐药突变。在此，我们报告了一例接受过大量预处理的晚期L1951R和L2026M突变ROS1重排NSCLC患者，该患者最初对repotrectinib有反应，但后来随着L2086F突变的出现进一步产生了靶向耐药。随后，该患者对卡博替尼（一种针对 L2086F 具有临床前活性的独立 ROS1 TKI）产生了反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report

Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against G2032R, the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretreated, with advanced L1951R and L2026M mutated ROS1-rearranged NSCLC, who initially responded to repotrectinib but later developed further on-target resistance with the emergence of an L2086F mutation. The disease then responded to cabozantinib, a separate class of ROS1 TKI with preclinical activity against L2086F.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks